Kancera AB (publ)

Stockholm Stock Exchange KAN.ST

Kancera AB (publ) Gross Profit Margin for the year ending December 31, 2023: 100.00%

Kancera AB (publ) Gross Profit Margin is 100.00% for the year ending December 31, 2023, a 91.60% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Kancera AB (publ) Gross Profit Margin for the year ending December 31, 2022 was 52.19%, a -35.74% change year over year.
Kancera AB (publ) Gross Profit Margin for the year ending December 31, 2021 was 81.22%, a 16.03% change year over year.
Kancera AB (publ) Gross Profit Margin for the year ending December 31, 2020 was 70.00%, a -27.85% change year over year.
Kancera AB (publ) Gross Profit Margin for the year ending December 31, 2019 was 97.01%, a 21.44% change year over year.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

Stockholm Stock Exchange: KAN.ST

Kancera AB (publ)

CEO	Mr. Peter Selin
IPO Date	Feb. 25, 2011
Location	Sweden
Headquarters	Karolinska Institutet Science Park
Employees	5
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Kancera AB (Publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase I study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the treatment of ovarian cancer. It also develops HDAC for the treatment of nerve inflammation and pain; and ROR1 inhibitors for the treatment of solid tumors and blood cancers. Kancera AB (Publ) was founded in 2010 and is based in Solna, Sweden.

Key trends

Past 5 years